BIIB vs CODX · P/E 21, rev $9.89B vs rev $3.9M
Biogen Inc (BIIB) versus Co-Diagnostics, Inc. Common Stock (CODX) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. CODX currently screens at market cap $31.4M.
Not investment advice. Open the BIIB and CODX stock pages for the full models.
Not investment advice.